三阳型乳腺癌的临床病理学特点及辅助治疗

doi:10.11904/j.issn.1002-3070.2020.03.014

Abstract

Abstract: Triple positive breast cancer is a special type of breast cancer.Although the incidence is low,this type of breast cancer is prone to axillary lymph node metastasis and distant metastasis.These clinicopathological characteristics have attracted great attention.Therefore,the choice of adjuvant therapy options has become an important factor affecting the prognosis of patients with triple positive breast cancer.This review is to integrate the research results from domestic and international to provide a more reasonable individualized treatment plan for patients with triple positive breast cancer.

Key words: Molecular typing, Triple positive breast cancer, Adjuvant treatment

CLC Number:

R730.5

LI Hui,PANG Da. Clinicopathological characteristics and adjuvant treatment of triple positive breast cancer[J]. Journal of Practical Oncology, 2020, 34(3): 262-265.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2020.03.014

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2020/V34/I3/262

References

1 Simpson PT,Reis-Filho JS,Lakhani SR.Breast pathology:beyond morphology[J].Semin Diagn Pathol,2010,27(1):91-96.
2 周晓蝶,王健,孟刚.三阳型乳腺癌的临床病理特征和预后[J].临床与实验病理学杂志,2014,30(5):483-487.
3 汪玲,潘华锋,李琰.不同分子分型乳腺癌临床病理特征及预后分期分析[J].临床外科杂志,2019,27(3):231-234.
4 高建超,费乐学.不同分子分型的乳腺癌患者个体化用药研究[J].中国现代普通外科进展,2017,20(5):389-393.
5 卢振东,孙晓晓,谢龙祥,等.乳腺癌分子分型研究进展[J].河南大学学报(医学版),2018,37(4):229-233.
6 Arpino G,Wiechmann L,Osborne CK,et al.Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family:molecularmechanism and clinical implications for endocrine therapy resistance[J].Endocr Rev,2008,29(2):217-233.
7 Prat A,Baselga J.The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2[J].Nat Clin Pract Oncol,2008,5(9):531-542.
8 Ben VC,Isabelle VB,Maria D,et al.Axillary lymph node status of operable breast cancers by combined steroid receptor and HER2 status:triple positive tumours are more likely lymph node positive[J].Breast Cancer Res Treat,2009,113(1):181-187.
9 Alwan NAS,Mualla FH,Al Naqash M,et al.Clinical and pathological characteristics of triple positive breast cancer among Iraqi patients[J].Gulf J Oncolog,2017,1(25):2078-2101.
10 谢菲,王珏,朱倩男,等.乳腺癌分子分型与腋窝淋巴结转移的临床研究[J].中国肿瘤外科杂志,2018,10(3):147-149.
11 Simon SD,Bines J,Werutsky G,et al.Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil:The AMAZONA retrospective cohort study[J].The Breast,2019,44:113-119.
12 Chas M,Boivin L,Arbion F,et al.Clinicopathologic predictors of lymph node metastasis in breast cancer patients according to molecular subtype[J].Gynecol Obstet Hum Reprodt,2018,47(1):9-15.
13 Arpino G,Weiss H,Lee AV,et al.Estrogen receptor-positive,progesterone receptor-negative breast cancer:association with growth factor receptor expression and tamoxifen resistance[J].J Natl Cancer Inst,2005,97(17):1254-1261.
14 Parise CA,Caggiano V.Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers[J].J Cancer Epidemiol,2014,2014:469251.
15 Purdie CA,Quinlan P,Jordan LB,et al.Progesterone receptor expression is an independent prognostic variable in early breast cancer:a population-based study[J].Br J Cancer,2014,110(3):565-572.
16 Hayashi N,Niikura N,Yamauchi H,et al.Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer[J].Breast Cancer Res Treat,2013,137(2):523-531.
17 汪霖,孟祥宁.人类表皮生长因子受体2阳性肿瘤靶向药物研究进展[J].实用肿瘤学杂志,2016,30(3):266-270.
18 Slamon DJ,Leyland-Jones B,Shak S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J Med,2001,344(11):783-792.
19 Kaufman B,Mackey JR,Clemens MR,et al.Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive,hormone receptor-positive metastatic breast cancer:results from the randomized phase III TAnDEM study[J].J Clin Oncol,2009,27(33):5529-5537.
20 Iancu G,Vasile D,Iancu RC,et al.“Triple positive” breast cancer-a novel category?[J].Rom J Morphol Embryol,2017,58(1):21-26.
21 Vici P,Pizzuti L,Natoli C,et al.Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras(1):a real-world multicenter observational analysis.The RETROHER study[J].Breast Cancer Res Treat,2014,147(3):599-607.
22 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊疗指南与规范(2017版)[J].中国癌症杂志,2017,27(9):695-760.
23 Denduluri N,Somerfield MR,Eisen A,et al.Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2(HER2)-negative and adjuvant targeted therapy for HER2-positive breast cancers:an American Society of Clinical Oncology Guideline adaptation of the Cancer Care Ontario Clinical Practice Guideline[J].J Clin Oncol,2016,34(20):2416-2427.
24 Gianni L,Pienkowski T,Im YH,et al.Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced,inflammatory,or early HER2-positive breast cancer(NeoSphere):a randomised multicentre,open-label,phase 2 trial[J].Lancet Oncol,2012,13(1):25-32.
25 Schneeweiss A,Chia S,Hickish T,et al.Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer:a randomized phase II cardiac safety study(TRYPHAENA)[J].Ann Oncol,2013,24(9):2278-2284.
26 Grazia A,Carolina G,Heidi W,et al.Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy[J].J Natl Cancer Inst,2007,99(9):694-705.
27 Finn RS,Dering J,Conklin D,et al.PD 0332991,a selective cyclin D kinase 4/6 inhibitor,preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro[J].Breast Cancer Res,2009,11(5):77.

Clinicopathological characteristics and adjuvant treatment of triple positive breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 1

Recommended Articles

Metrics

Comments